Building on Its Recent Acquisition of the CCX0722 Intellectual Property, Cosmos Health Owns the Technology Outright and Is Now Pursuing Patent Protection Across Four Major Healthcare Markets Within the $190+ Billion Global Weight Management Category
- Advances international patent application WO2025108566A1, titled “Hydrogel for Body Weight Management,” into the U.S., Europe, Australia, and Canada — four of the world’s largest healthcare markets
- Builds on Cana Laboratories’ acquisition of the patent application from Cloudpharm, bringing full ownership of the underlying intellectual property into the Cosmos Health portfolio, with no licensing fees, royalty-sharing, or third-party IP dependency
- Three-plus years of disciplined R&D execution — from concept in 2022 through pilot production, scale-up, and final-stage development
- Positioned within the rapidly growing global weight management market, estimated at $190.6 billion in 2025 and projected to reach $562.2 billion by 2033 at a 14.2% CAGR, as obesity becomes one of healthcare’s most capital-intensive categories
- Management believes CCX0722 represents one of Cosmos Health’s most strategically significant proprietary assets, with multiple potential paths to value creation — including licensing, co-development, and strategic partnerships
Recent Comments